2020-12-02

Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US

Camurus AB today announced that Camurus licensee Braeburn has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Brixadi.

Read the full press release: https://www.camurus.com/

Latest news

2019-04-10

Aimpoint granted new large FCS contract from the U.S. Military

Aimpoint has been awarded a large contract of USD 24 million from the U.S. Military for the FCS13-RE system for SAAB…

Read more

2019-04-10

Camurus’ rights issue oversubscribed

Camurus’ rights issue of 403 MSEK has been oversubscribed. The rights issue was carried out to secure financing of t…

Read more

2019-04-10

Positive results for Buvidal® in treatment for fentanyl dependence

New positive results from a Phase 3 study show that Camurus’ Buvidal® provides better treatment effect for fentanyl…

Read more

2019-04-10

Court proceedings initiated for immediate market approval of Brixadi™ in the US

Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and…

Read more

2019-02-26

Spin-off of GAIM from Aimpoint

Based on Aimpoint's red dot sight for fire arms, the company has developed a commercial VR platform, GAIM, which is…

Read more